SCHEMBL17138490

SCHEMBL17138490

CCN1CCCN(CC2(C)CO2)C1=O

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PER2 O15055 3/20 0.36
CRY2 Q49AN0 1/20 0.33
INMT O95050 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6365391 0.79 PER2 (0.46) PER2CRY2INMT
SCHEMBL10416543 0.74 PER2 (0.42) PER2CRY2INMT
SCHEMBL8854156 0.72 PER2 (0.41) PER2CRY2INMT
SCHEMBL5539716 0.70 KMT2A (0.54)
SCHEMBL329869 0.70 F2 (0.45) PER2CRY2INMT
SCHEMBL5540098 0.69 ERCC1 (0.52)
SCHEMBL5547302 0.68 RAB9A (0.54)
SCHEMBL5539132 0.68 HSD11B1 (0.46)
SCHEMBL5536636 0.68 PIK3CD (0.40) PER2CRY2
SCHEMBL11934366 0.67 PER2 (0.42) PER2CRY2INMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190837-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYCHRONICITY PHARMA INC (US) 2024-06-13 US disclosed
US-20220411399-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYCHRONICITY PHARMA INC (US) 2022-12-29 US disclosed
US-20220411399-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYCHRONICITY PHARMA INC (US) 2022-12-29 US disclosed
CN-110003172-B Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators 同步制药公司 2022-04-01 CN disclosed
EP-3939971-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. (US) 2022-01-19 EP disclosed
EP-3939971-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. (US) 2022-01-19 EP disclosed
US-20210171495-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2021-06-10 US disclosed
US-20210171495-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2021-06-10 US disclosed
EP-3129366-B1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYNCHRONICITY PHARMA INC (US) 2021-06-09 EP disclosed
EP-3129366-B1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYNCHRONICITY PHARMA INC (US) 2021-06-09 EP disclosed
US-10759777-B2 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators Synchronicity Pharma, Inc. (US) 2020-09-01 US disclosed
US-20190241540-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2019-08-08 US disclosed
US-20190241540-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2019-08-08 US disclosed
US-20180334446-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2018-11-22 US disclosed
US-10005759-B2 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2018-06-26 US disclosed
US-10005759-B2 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2018-06-26 US disclosed
WO-2015157182-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS RESET THERAPEUTICS, INC. (US) 2015-10-15 WO disclosed
US-20150284362-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2015-10-08 US disclosed
US-20150284362-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2015-10-08 US disclosed
US-20150284362-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2015-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241540-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS PER2 188/4885CRY2 2/4885INMT 967/4885
US-20150284362-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS PER2 188/4885CRY2 2/4885INMT 967/4885
US-20180334446-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS PER2 188/4885CRY2 2/4885INMT 967/4885
US-20210171495-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS PER2 188/4885CRY2 2/4885INMT 967/4885
US-10759777-B2 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators CRY1, CRY2, HCCS PER2 188/4885CRY2 2/4885INMT 967/4885
US-20220411399-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS PER2 188/4885CRY2 2/4885INMT 967/4885
US-10005759-B2 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators CRY1, CRY2, HCCS PER2 188/4885CRY2 2/4885INMT 967/4885
US-20240190837-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS PER2 188/4885CRY2 2/4885INMT 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.